Page 5 - மருந்து கட்டுப்பாடு அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
As Covid vaccinations gather pace, Khairy admits still a ways to go in bid to immunise 80pc of Malaysians | Malaysia
malaymail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaymail.com Daily Mail and Mail on Sunday newspapers.
Our vaccination rate accelerated in line with Covid-19 situation
harakahdaily.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from harakahdaily.net Daily Mail and Mail on Sunday newspapers.
Vaccination accelerated in line with current Covid-19 situation: Khairy | Daily Express Online
dailyexpress.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexpress.com.my Daily Mail and Mail on Sunday newspapers.
KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst.
It said on Monday it was keeping its forecasts intact for now pending the details or further developments in the supply agreement for the Sinopharm vaccine, which it thinks could be signed by end of the month.
“We retain our Add call on the stock with an unchanged TP of RM3.67 based on a CY22F P/E of 28.8 times (+2 standard deviations from its five-year mean),” the research house said.
The Health Ministry said the Drug Control Authority (DCA) made the decision at a meeting yesterday.
“This conditional registration approval requires information on the quality, safety and effectiveness of the vaccine product to be monitored and evaluated based on the latest data from time to time.
“It is to ensure that the benefits outweigh the risks for the vaccines,” it said in a statement.
The ministry said it strove to combat the pandemic by ensuring an adequate supply of vaccines that had been evaluated for quality, safety and effectiveness by the National Pharmaceutical Regulatory Division and approved by the DCA.